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Abstract 
Background 
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder in which infection 
with Chlamydia pneumoniae (Cpn) has been associated. Cpn is an obligate intracellular 
respiratory pathogen that may enter the central nervous system (CNS) following infection and 
trafficking of monocytes through the blood-brain barrier. Following this entry, these cells 
may secrete pro-inflammatory cytokines and chemokines that have been identified in the AD 
brain, which have been thought to contribute to AD neurodegeneration. The objectives of this 
work were: (i) to determine if Cpn infection influences monocyte gene transcript expression 
at 48 hours post-infection and (ii) to analyze whether pro-inflammatory cytokines are 
produced and secreted from these cells over 24 to 120 hours post-infection. 
Methods 
Gene transcription was analyzed by RT-PCR using an innate and adaptive immunity 
microarray with 84 genes organized into 5 functional categories: inflammatory response, host 
defense against bacteria, antibacterial humoral response, septic shock, and cytokines, 
chemokines and their receptors. Statistical analysis of the results was performed using the 
Student's t-test. P-values ≤ 0.05 were considered to be significant. ELISA was performed on 
supernatants from uninfected and Cpn-infected THP1 monocytes followed by statistical 
analysis with ANOVA. 
Results 
When Cpn-infected THP1 human monocytes were compared to control uninfected monocytes 
at 48 hours post-infection, 17 genes were found to have a significant 4-fold or greater 
expression, and no gene expression was found to be down-regulated. Furthermore, cytokine 
secretion (IL-1β, IL-6, IL-8) appears to be maintained for an extended period of infection. 
Conclusions 
Utilizing RT-PCR and ELISA techniques, our data demonstrate that Cpn infection of THP1 
human monocytes promotes an innate immune response and suggests a potential role in the 
initiation of inflammation in sporadic/late-onset Alzheimer’s disease. 
Keywords 
Chlamydia pneumoniae, Inflammation, Innate immunity, Alzheimer’s disease, Gene 
expression 
Background 
Studies from our laboratory have implicated infection with Chlamydia pneumoniae (Cpn) in 
the pathogenesis of sporadic late-onset Alzheimer’s disease (LOAD) [1-3]. We have 
previously identified infection within monocytes, macrophages, microglia, astroglia, and 
neurons in the Alzheimer's disease (AD) brain. One mechanism by which the organism may 
gain access into the brain is following peripheral infection of monocytes [4,5]. We are 
investigating Cpn infection of monocytes in vitro to determine how infection may promote 
changes in inflammatory gene and protein expression because monocytes have been 
demonstrated to be altered with regards to expression of cytokines, Aβ amyloid clearance, 
and apoptosis in Alzheimer's disease patients [6-9]. 
Although the specific etiology of LOAD has remained elusive, what has emerged is strong 
evidence that inflammation is a focal point in the neuropathogenesis process [10-13]. 
Associations between AD and many inflammatory biomarkers, including IL-1β, IL-2, IL-4, 
IL-6, IL-8, IL-10, IL-12, IL-18, IFN-γ, TNF-α, tumor growth factor beta (TGF-β), and C-
reactive protein (CRP) have all been well documented [14] (for reviews see [12,14]). 
Activated microglia and astroglia have been identified near and around neuritic senile plaques 
in the AD brain along with pro-inflammatory cytokines IL-1β, IL-6, and TNF-α 
[11,13,15,16], suggesting that a pro-inflammatory state could be responsible for neurotoxicity 
associated with AD [17]. 
As the primary immune cells within the human brain, microglia act as the functional 
equivalent of macrophages inside the central nervous system (CNS) [18]. Microglia are 
activated in response to an infection or injury within the brain and are speculated to be 
responsible for neurotoxicity in diseases such as multiple sclerosis and Parkinson’s disease 
[18,19]. Experiments in rats have shown that microglia phagocytize and internalize amyloid, 
apparently in an effort to clear amyloid from the CNS [20]. Related data also indicate that 
following phagocytosis, Aβ amyloid may remain stored and un-degraded within the activated 
microglia [21]. 
Microglial activation as a consequence of internalization of Aβ may activate neighboring 
microglia and astrocytes through a 'bystander effect'. These activated glia, in turn, may 
promote further Aβ 1-40 and 1-42 production [22]. This cycle appears to perpetuate 
inflammation, as well as Aβ production and deposition [10,23]. Activated microglia release a 
pool of pro-inflammatory factors including IL-1β, IL-6, TNF-α, nitric oxide, IL-8, and 
macrophage inflammatory protein-1 [24,25]. As IL-1β and IL-6 are major pro-inflammatory 
cytokines involved with neuronal dysfunction, glia producing these cytokines may start a 
self-activating cascade referred to as a lethal 'cytokine cycle' [10,11,25]. According to the 
cytokine cycle, IL-1 is released from activated glia across AD brain regions independent of 
the initial stimulus. This primary event drives the cascade of cytokine release which promotes 
the neuropathological changes associated with AD. 
A correlation between activated astroglia and amyloid plaques appears to exist, as astroglia, 
which greatly outnumber microglia in the brain, often aggregate at the site of Aβ deposits 
[26,27]. Substantial evidence indicates that astroglia are directly involved in the degradation 
and clearance of Aβ [26], and when activated, they also promote inflammation by secreting 
IL-1β and IL-6 [28]. These pro-inflammatory mediators also have been shown to activate 
astroglia resulting in an increased production of Aβ 1-40/1-42 peptides, thus demonstrating a 
positive feedback loop for the generation of amyloid [23,29]. Chronic glial activation may 
perpetuate a chain reaction where successive axonal target regions fall victim to additional 
neuronal damage, thereby continuing the cycle [11]. 
Furthermore, astroglia have been shown to generate other pro-inflammatory mediators such 
as monocyte chemoattractant peptide-1 (MCP1/CCL2), RANTES, and TNF-α in reaction to 
the presence of Aβ [30]. CCL2 is a potent chemoattractant molecule for monocytes, and thus, 
monocytes may be both initiators and perpetuators of the cycle, suggesting that monocytes 
could be significant contributors to the pro-inflammatory cascade. 
The current study addresses infection of human THP1 monocytes in vitro with the laboratory 
strain of Cpn, AR39, to determine how infection can affect the regulation of gene transcripts 
for innate and adaptive immunity. In this regard, infection may be a stimulus for pro-
inflammatory cytokine expression which may start the cascade that results in initial amyloid 
processing and deposition observed in Alzheimer's disease [1,31,32]. Analysis of this 
cytokine expression will demonstrate how infection of monocytes could set the stage for 
initiating inflammation in this disease. 
Materials and methods 
THP1 human monocytes 
THP1 human monocytes obtained from the American Type Culture Collection (ATCC, 
Manassas, VA, USA), were propagated at a concentration of 1 x 10
6
 cells/ml RPMI 1640 
(ATCC) + 10% FBS (Cellgro Thermo Fisher Scientific, Pittsburgh, PA, USA) growth media 
(GM) in a 37?C incubator with 5% CO 2. 
  
Infection with Chlamydia pneumoniae (Cpn) 
A human respiratory isolate of Cpn, laboratory strain AR39 obtained from the ATCC, was 
used to infect THP1 monocytes in vitro. Prior to inoculation of monocytes, each vial of Cpn 
was thawed and sonicated for 2 minutes. THP1 cells were spun down, washed with Hank’s 
Balanced Salt Solution (HBSS), and resuspended in 1 ml of GM at a concentration of 1 x 10
6
 
cells/ml. To this volume, 400 μl of Cpn at a multiplicity of infection (MOI) of 1 (1 x 106 
infectious units IFU) were added. The cells were allowed to incubate for 1 hour at 37?C with 
5% CO2 in a T-25 flask, after which 3.6 ml of GM was added for a final volume of 5 ml. 
Cells were then incubated for the allotted times (24 to 120 hours). For 96- and 120-hour 
infections, another 5 ml of GM was added at the 48-hour time point. 
To validate and determine percent of infection of our monocytes at each time point, 2 x 10
5
 
cells at 1 x 10
5
 cells per slide were cytospun and analyzed by immunocytochemistry. In brief, 
cytospun cells were fixed using Cytofix/Cytoperm (BD Cytofix/Cytoperm 554722; BD 
Biosciences, San Jose, CA, USA) for 30 minutes, washed 2 x 5 minutes with HBSS, labeled 
with a fluorescein isothiocynanate (FITC)-directly conjugated anti-chlamydial antibody, 
Fitzgerald 61C75 (Fitzgerald Industries International, Acton, MA, USA) for 1 hour at 37?C, 
and counterstained using bisbenzimide (Sigma bisbenzimide B2883, Sigma-Aldrich, St 
Louis, MO, USA) and coverslipped. The slides were imaged on a Nikon E80i microscope 
using the NIS-Elements AR 3.0 software (Nikon Inc., Melville, NY, USA). Five random 
fields per slide per time point for each experiment at 40X magnification were analyzed and 
counted (total infected cells/total cells x 100 = percent infected). Average percent infection 
for 24 to 120 hours was 81, 85, 92, 92, and 90, respectively. 
Infection time for the real time-polymerase chain reaction (RT-PCR) experiments was 48 
hours and the infection times for the ELISA cytokine analyses were 24 to 120 hours. 
Although gene changes were analyzed only at 48 hours post-infection, the time at which an 
acute infection is established, we wanted to obtain specific data for cytokine changes over 
longer time points as the inflammation in AD appears to become more chronic in nature 
following its initiation. In a comparable manner, parallel control uninfected flasks at the same 
cellular concentration received only media for the specified incubation times. 
At the specified times for analysis, both uninfected and infected cells were removed from the 
incubator and transferred to individual 15-ml tubes. To ensure complete cell recovery, 
another 5 ml of fresh GM was added to the 24-, 48- and 72-hour flasks, followed by cell 
scraping to release any remaining cells prior to transfer to the 15-ml tubes. The final volume 
for all time points was 10 ml. The cells were pelleted at 1,000 x g for 5 minutes. The 
supernatants were collected for ELISA analysis into new 15-ml tubes and frozen at −80°C. 
The pellet was resuspended in 5 ml of HBSS and counted. Cells were again pelleted and 
either kept on ice or snap frozen in liquid nitrogen prior to preparation for RT-PCR. 
  
RNA isolation 
Using the RNeasy Mini kit (Qiagen Inc., Valencia, CA, USA), RNA was extracted from cell 
pellets according to manufacturer’s directions. In brief, cells were mixed with RLT buffer, 
pipetted onto a QIAshredder™ spin column and centrifuged for 2 minutes at 15,000 x g to 
lyse and homogenize the cells. Ethanol was mixed with this sample, transferred to an RNeasy 
spin column, centrifuged for 15 seconds at 8,000 x g and the flow-through discarded. RW1 
Buffer (700 μl) was added, centrifuged for 15 seconds at 8,000 x g and flow-through 
discarded. RPE Buffer (500 μl) was added to the RNeasy spin column, centrifuged for 15 
seconds at 8,000 x g, flow-through discarded, another 500 μl of RPE Buffer was added and 
centrifuged for 2 minutes at 8,000 x g. Finally, the RNA was eluted from the spin column in 
RNase-free water (30 μl). 
First strand synthesis 
Using the RT
2
 First Strand Kit (SABiosciences, Qiagen, Valencia, CA, USA), cDNA was 
produced from 1 μg of RNA following the First Strand Kit protocol according to 
manufacturer’s directions. To eliminate any contaminating genomic DNA carryover, a 
Genomic DNA Elimination step preceded the reverse transcription reaction. Following 
reverse transcription, 91 μl of RNase, DNase-free water was added to each 20 μl of cDNA. 
This cDNA was either used immediately for RT-PCR or frozen at −20°C until use. 
Real time-polymerase chain reaction (RT-PCR) 
RT-PCR was used to determine the level of gene transcription using the Human Innate and 
Adaptive Immune Responses RT
2
 Profiler™ PCR Array (PAHS-052) from SABiosciences 
(Qiagen, Valencia, CA, USA). The cDNA samples were spun briefly to remove any 
particulate material. The master mix cocktail was prepared according to the specifications for 
the 96-well plate. 
Twenty-five microliters of the experimental cocktail was added to each well of the 96-well 
RT-PCR array plate. The plate was run on the Applied Biosciences 7000 Sequence Detection 
System (Life Technologies Corporation, Carlsbad, CA, USA) utilizing ABI Prism 7000 SDS 
Software and then analyzed using software on the SABiosciences website [33]. The data are 
normalized to the control housekeeping genes RPL13A, GAPDH and ACTB. The website 
calculates fold change (fold difference) by the 2
-ΔΔ
CT method with the control being the 
uninfected THP1 cells. Statistical analysis of the results was done using Student’s t-test. P-
values below 0.05 were considered to be significant. RT-PCR experiments were performed 
using cDNA from 4 separate experiments comparing 48 hour Cpn-infected THP1 monocytes 
to parallel uninfected monocytes grown for 48 hours. 
Multi-analyte ELISA array 
Using the Multi-Analyte ELISArray Kit protocol version 1.4 from SABiosciences (Qiagen, 
Valencia, CA, USA), a multi-array ELISA was performed using the supernatants collected 
during the harvest of uninfected and Cpn-infected THP1 monocytes according to 
manufacturer’s directions. In brief, the supernatants were thawed and centrifuged for 10 
minutes at 1,000 x g to remove any particulate material. Fifty microliters of each 
experimental sample, in triplicate, was added to the array that included specific cytokine 
capture antibodies: IL-1α IL-1β, IL-2, IL-4, IL-6, IL-8, IL-12, IL-17α, IFN-γ, TNF-α and GM 
CSF (colony stimulating factor) and allowed to incubate at room temperature (RT) for 2 
hours. 
After numerous buffer washes, 100 μl of the diluted biotinylated detection antibodies were 
added to the appropriate wells of the ELISA plate and incubated in the dark for 1 hour at 
room temperature (RT). Following this incubation, the plate was washed and 100 μl of dilute 
Avidin-horseradish peroxidase (HRP) were added into all wells and incubated in the dark for 
30 minutes at RT. After this incubation, development and stop solutions were added followed 
by detection of absorbance changes at 450 and 570 nm on a UV/VIS spectrophotometer 
(Nicolet Evolution 100, Thermo Fisher Scientific, Pittsburgh, PA, USA). 
The raw data obtained from the absorbance readings were normalized to the cell counts of 
each sample. Averages of all triplicates were determined along with standard deviations and 
an analysis of variance (ANOVA) statistical test was performed. Time points of 24, 48 and 
72 hours were tested in triplicate in 5 separate experiments, while the 96- and 120-hour time 
points were tested in triplicate in 4 separate experiments. 
Single-analyte ELISA array 
Using the Single-Analyte ELISArray Kit protocol version 1.4 from SABiosciences (Qiagen, 
Valencia, CA, USA), a single-analyte ELISA was performed for IL-1β, IL-6, and IL-8 
according to manufacturer’s directions using the supernatants collected during the harvest. In 
brief, the supernatants were thawed and centrifuged for 10 minutes at 1,000 x g to remove 
any particulate material. Preparation of the antigen standard dilution was prepared by serial 
dilution. As with the multi-analyte array, the array was prepared using 50 μl of each 
experimental sample in triplicate and allowed to incubate at RT for 2 hours, followed by 
incubation with the detection antibodies. Similar to the previous multi-analyte arrays, Avidin-
HRP was used to determine binding of the detection antibodies to the cytokines of interest. 
After color development as described above, absorbance readings were taken at 450 and 570 
nm and the raw data were normalized. Averages of all triplicates were found along with 
standard deviations and an ANOVA statistical test was performed. As with the multi-analyte 
array, times of 24, 48 and 72 hours were tested in 5 separate experiments and those of 96 and 
120 hours were tested from 4 separate experiments. 
Results 
Real time-polymerase chain reaction 
Gene transcription was analyzed by RT-PCR using an innate and adaptive immunity 
microarray with 84 genes organized into 5 functional categories: inflammatory response, 
septic shock, cytokines, chemokines and their receptors, host defense against bacteria, and 
antibacterial humoral response. When Cpn-infected THP1 human monocytes were compared 
to control uninfected monocytes at 48 hours post-infection, 17 gene transcripts (Table 1) had 
significant increases (P-values ≤ 0.05). 
  
Table 1 Innate and adaptive immunity gene transcripts increased at 48 hours in 
Chlamydia pneumoniae (Cpn)-infected THP1 cells 
 Gene symbol Gene name 
Inflammatory response IL1F5 Interleukin 1 family, member 5 (delta) 
IL1F8 Interleukin 1 family, member 8 (eta) 
IL1RN Interleukin 1 receptor antagonist 
IRAK2 Interleukin 1 receptor associated kinase 2 
NLRC4 NLR family, CARD domain containing 4 
TLR8 Toll-like receptor 8 
TNF Tumor necrosis factor (TNF superfamily, member 2) 
Host defense against bacteria DEFB4 Defensin, beta 4 
DMBT1 Deleted in malignant brain tumors 1 
NFKBIA Nuclear factor of kappa light polypeptide gene enhancer in 
B-cells inhibitor, alpha 
PTAFR Platelet-activating factor receptor 
Antibacterial response COLEC12 Collection sub-family member 12 
CYBB Cytochrome B-245, beta polypeptide 
Cytokines, chemokines, and their 
receptors 
CCL2 Chemokine (C-C motif) ligand 2 
IFNB1 Interferon, beta 1, fibroblast 
IL6 Interleukin 6 (Interferon, beta 2) 
Septic shock SERPINA1 Serpin peptidase inhibitor, clade A  
(alpha-1 antiproteinase, antitrypsin), member 1 
Transcripts analyzed included those associated with the host response to pathogens, including 
inflammatory response genes, antibacterial humoral response genes, cytokines, chemokines 
and their receptors, genes involved in bacterial host defense mechanisms and septic shock. 
Seven gene transcripts from the inflammatory response category (see Table 1 and Figure 1) 
had at least a four-fold increase in expression. Toll-like receptor (TLR)8 transcripts had the 
most dramatic significant fold increase of 33.73, whereas lesser increases were observed for 
TNF (4.26), NLRC4 (4.34), IL1F5 (8.79), IL1F8 (11.29), and the IL-1 receptor genes IL1RN 
(10.83) and IRAK2 (6.66). 
Figure 1 Inflammatory response, cytokines, chemokines and their receptors, and septic 
shock gene transcripts. Transcript increases of THP1 human monocytes at 48 hours post 
Cpn infection. Only significant gene transcripts with a 4-fold or greater increase compared to 
uninfected THP1 cells are included (P-values ≤ 0.05). 
Gene transcripts for 3 cytokines, chemokines and their receptors demonstrated significant > 
4-fold increases (Figure 1). CCL2 transcripts had the most dramatic significant fold increase 
of 1,136.10 within this category. Expression of IFNB1 and IL-6 both had significant increases 
of 11.02 and 6.69, respectively. Under septic shock (Figure 1), only 1 gene (SERPINA1, 
16.50) was found to have a significant increase in expression. 
Transcript changes with regard to the host defense against bacteria revealed four gene 
transcripts to be significantly up-regulated with > four-fold increases (Figure 2). PTAFR had 
the most dramatic significant increase in expression with 22.47 fold change. Under 
antibacterial humoral response (Figure 2), CYBB gene expression had the most significant 
increase of 17.15, while COLEC12 had a significant increase of 5.64. 
  
Figure 2 Host defense against bacteria and antibacterial humoral response gene 
transcripts. Gene transcript increases of THP1 human monocytes at 48 hours post Cpn 
infection. Only significant gene transcripts with a 4-fold or greater increase compared to 
uninfected THP1 cells are included; data are plotted on a log scale, (P-values ≤ 0.05). 
In summary, of all the 84 genes in the Innate and Adaptive Immunity pathway microarray, 
expression of CCL2 showed the most dramatic significant increase. Other cytokine gene 
transcripts of note such as IL-6 and TNF showed smaller, but significant fold increases in 
expression. 
ELISA 
ELISA techniques were performed using the supernatants of uninfected and Cpn-infected 
THP1 human monocytes. A multi-analyte ELISArray provided a general overview for 
secretion per 1 x 10
6
 cells of 12 cytokines. This ELISArray showed that the cytokines IL-1β, 
IL-6, and IL-8 have increased secretion when the cells are Cpn-infected, thus single-analyte 
ELISArrays were performed to further evaluate these 3 cytokines. 
IL-1β 
A single-analyte ELISArray for IL-1β (Figure 3) demonstrated a significant increase (P-value 
≤ 0.05) in cytokine secretion in the Cpn-infected THP1 human monocytes compared to 
uninfected THP1 cells for all the time points. In Cpn-infected THP-1 cells, a significant 
decrease in levels of secreted IL-1β at the 96-hour and 120-hour time points relative to the 
24-hour time point was observed. Decreased secretion of IL-1β also was significant for the 
Cpn-infected THP1 cells at the 72-, 96- and 120-hour time points compared to the levels at 
48 hours. At 120 hours, there was significantly lower secretion of IL-1β compared to 72 
hours. 
Figure 3 Average secretion of IL-1β. Average secretion of IL-1β by 106 cells at the 24-, 48- 
and 72-hour time points repeated in 5 individual experiments, and the 96 hours and 120 hours 
repeated in 4 individual experiments. The (*) symbol indicates significance (P-value ≤ 0.05) 
within time points (uninfected to infected), while the (#) symbol indicates significance (P-
value ≤ 0.05) between time points (infected to infected). 
IL-6 
Analysis of the IL-6 single-analyte ELISArray plate revealed that more IL-6 is secreted from 
Cpn-infected THP1 cells than uninfected THP1 cells at all times (Figure 4); this difference 
was significant. Moreover, there was an overall significant decrease in IL-6 secretion from 
Cpn-infected THP1 cells over the entire time course of infection. 
Figure 4 Average secretion of IL-6. Average secretion of IL-6 by 10
6
 cells at the 24-, 48- 
and 72-hour time points repeated in 5 individual experiments and the 96 hours and 120 hours 
repeated in 4 individual experiments. The (*) symbol indicates significance (P-value ≤ 0.05) 
within time points (uninfected to infected), while the (#) symbol indicates significance (P-
value ≤ 0.05) between time points (infected to infected). 
IL-8 
Results of the IL-8 single-analyte ELISArray plate revealed an initial significant increase (P-
value ≤ 0.05) in the 24-, 48-, 72-, 96- and 120-hour time points between Cpn-infected cells 
compared to uninfected THP1 (Figure 5). Similar to what was observed with IL-1β, at 96 and 
120 hours, there was a marked decrease in secretion of IL-8 from the Cpn-infected THP1 
cells compared to the Cpn-infected cells at earlier time points. Furthermore, the decreases 
seen at 96 and 120 hours as compared to 24 and 48 hours were significant (P-value ≤ 0.05), 
as was the decrease seen from the 48-hour time to the 72-hour time point, and the decrease 
seen from 72 hours to the 96- and 120-hour time points. 
Figure 5 Average secretion of IL-8. Average secretion of IL-8 by 10
6
 cells at the 24-, 48- 
and 72-hour time points repeated in 5 individual experiments and the 96 hours and 120 hours 
repeated in 4 individual experiments. The (*) symbol indicates significance (P-value ≤ 0.05) 
within time points (uninfected to infected), while the (#) symbol indicates significance (P-
value ≤ 0.05) between time points (infected to infected). 
Discussion 
Chlamydial species have been associated with a spectrum of diseases of clinical significance 
shown to be a result of immunopathogenesis. Although the immune response is central for 
disease manifestations, there is still much to learn about the mechanisms that initiate and 
sustain the inflammatory response to Cpn infection [34,35]. Secretion of pro-inflammatory 
cytokines occurs when host cells, including monocytes and microglia, are infected with Cpn 
[35,36]. The current study evaluates changes in THP1 monocyte gene expression at 48 hours 
post-infection (acute) and in specific cytokine production/secretion over a 5-day (chronic) 
course of infection. Our data indicate that infection of monocytes with Cpn results in 
significant changes in host gene transcription and secretion of pro-inflammatory cytokines. 
Furthermore, cytokine secretion (IL-1β, IL-6, IL-8) appears to be maintained for an extended 
period of infection, suggesting that a more chronic or persistent infection can maintain the 
pro-inflammatory condition. Work by others has suggested that similar cytokines were 
secreted after Cpn infection of THP1 monocytes, although shorter periods of infection with a 
higher multiplicity of infection (ie, MOI = 5) were evaluated [37]. Thus, our data suggest that 
Cpn-infected monocytes at a modest level of infection (ie, MOI = 1) can promote an acute 
and sustained pro-inflammatory state. 
Previous work has shown that Cpn can infect multiple cell types including endothelial cells, 
epithelial cells, smooth muscle cells, and peripheral blood mononuclear cells [1,38,39]. Cpn-
infected macrophages have been found in sites such as the peritoneum and spleen following 
respiratory inoculation of New Zealand white rabbits [40]. These findings suggest that the 
migratory capabilities of peripheral blood monocytes may help to facilitate systemic infection 
[41]. Moreover, infection of human monocytes with Cpn appears to enhance their migration 
across an in vitro model of the blood-brain barrier (BBB) comprised of a human brain 
microvascular endothelial cell layer [4]. Previous studies have shown that infection in the 
lung is the main stimulus for monocytic and lymphocytic infiltration leading to potential 
dissemination of infection into the circulation [40,42]. Blood vessels and monocytes in AD 
brain tissue have been shown to be infected with Cpn, thus we postulate that Cpn entering the 
circulation upon infection of monocytes could result in access to the CNS through the BBB 
[4,5,43]. With regards to LOAD, Cpn has been studied as a possible etiologic agent [1,2] and 
supporting evidence for Cpn in the etiopathogenesis of AD was provided by a study by Little 
et al. 2004 which revealed amyloid deposits resembling plaques found in AD brains in the 
brains of non-transgenic BALB/c mice following intranasal infection with Cpn [42]. 
As discussed previously, numerous cytokines have been shown to be involved in 
neuroinflammation in AD, and previous work by others has implicated high levels of IL-1 
directly in neuronal degeneration [44,45]. IL-1β is a member of the interleukin 1 cytokine 
family and is produced by endothelial cells, some epithelial cells, and also by activated 
macrophages as a pro-protein, which is proteolytically processed to its active form by IL-1β 
convertase. This cytokine is an important mediator of the inflammatory response, and is 
involved in a variety of cellular activities, including cell proliferation, differentiation, and 
apoptosis [46]. Also, IL-1β activates nitric oxide synthase (NOS), which is implicated in 
neuronal damage, ultimately leading to cell death in hippocampal neurons [47]. Furthermore, 
IL-1β has been shown to play a part in the promotion of neuronal synthesis of β amyloid 
precursor protein (APP) and may enhance the transition from diffuse to fibrillar neuritic 
plaques [48]. Our data suggest that infection may play an early role in the etiology of AD, 
even before amyloid is produced. This contrasts with others who have focused previously on 
amyloid as being the principal stimulus for the activation of this cytokine [28]. 
The key debate, therefore, lies not in what this cytokine can activate and/or damage in the 
brain, but rather what initiates its production. Levels of IL-1β have been shown to be higher 
in the cerebrospinal fluid (CSF) of AD patients than in patients with vascular dementia or 
control patients [49,50]. Our data show that IL-1β is significantly up-regulated at all times 
through 120 hours post-infection of monocytes and thus is consistent with the cytokine 
profile in AD, suggesting that infection can be an initiating stimulus for this cytokine. 
Evidence suggests that IL-1β and IL-6 up-regulate the cdk5/p35 complex [51], a protein 
kinase involved in tau hyperphosphorylation, a major pathological process observed in AD. 
IL-6 also may be involved in neuronal degradation. IL-6 is an inflammatory cytokine that is 
secreted by leukocytes and other various cell types during infection [52]. As a pro-
inflammatory cytokine, IL-6 is secreted by T-cells, endothelial cells, and macrophages, which 
stimulate an immune response to tissue damage leading to inflammation in the surrounding 
area. IL-6 is an important mediator of fever and of the acute phase response. IL-6 can be 
secreted by macrophages in response to specific microbial molecules, referred to as pathogen 
associated molecular patterns (PAMPs), and can induce intracellular signaling cascades that 
can further give rise to inflammatory cytokine production [53]. Infection with Cpn, as we 
have determined in this study, influences significant secretion of this cytokine from infected 
monocytes. 
Not surprisingly, in our study, several gene transcripts were found to have significant fold 
increases in the group consisting of the host defense against bacteria. These included: 
DEFB4, DMBT1, PTAFR, and NFKBIA. DEFB4 is the transcript that codes for a defensin 
protein with antimicrobial activity that has been shown to act as a cytokine linking innate and 
adaptive immune responses [54]. Along these lines, Aβ amyloid 1-42 has been demonstrated 
to have antibacterial properties and has been speculated to act as an anionic defensin [55]. 
However, whether Aβ 1-42 production and processing in LOAD results, in part, as an 
antibacterial response is still debatable. Therefore, defensin transcript increases are intriguing 
and warrant further study. 
Up-regulation of DMBT1 takes place in response to activation of the intracellular pattern 
recognition molecule NOD2 and consecutive NFkB-activation; this hinders bacterial invasion 
and lipopolysaccharide (LPS)-induced TLR4 activation [56]. PTAFR is the gene for the 
platelet activating factor receptor, which plays a role in the inflammatory response [57]. 
NFKBIA could lead to inhibition of the NFκB protein complex by trapping this transcription 
factor in the cytoplasm, effectively leading to its inactivation. However, as NFκB activation 
is upstream of gene transcription for IL-1β mentioned above, its complete inactivation by 
NFKBIA up-regulation appears unlikely in our infected cells. 
Another interesting entity found to be activated in infected cells is the inflammasome 
complex. This is a cytoplasmic multi-protein complex that activates caspase-1, leading to the 
processing and secretion of pro-inflammatory cytokines. These complexes are associated 
with TLRs to mediate the response to extracellular and intracellular pathogens [58]. NLRC4 
(NLR family, CARD domain containing 4) is involved in the regulation of caspase-1, which 
upon activation results in processing and secretion of IL-1β. In this study, the NLRC4 gene 
transcript showed significant fold increases. Previously, others have shown that NLRC4 is 
required for the activation of caspase-1 and IL-1β secretion in response to bacterial flagellin 
[59]. Interestingly, inflammasome activation also may arise as an outcome of amyloid 
deposition and aggregation [60]. By orchestrating the activation of precursors of pro-
inflammatory caspases, which in turn activate IL-1β, IL-18 and IL-33 secretion, the 
inflammasome promotes a potent inflammatory response that influences the release of toxins 
from glial and endothelial cells [61]. Although the NLRC4 inflammasome has been shown to 
be activated by flagellated Gram-negative bacteria, recent studies have shown evidence for a 
flagellin-independent pathway that activates the NLRC4 inflammasome after infection with 
certain aflagellated bacteria [62]. As Cpn is an intracellular bacterium and aflagellated, our 
data would support that of a flagellin-independent pathway. Another important response to 
infection is one in which acute phase reactants are produced and secreted into blood. Of 
these, serpins are included and constitute the largest superfamily of protease inhibitors in 
humans [63,64]. In the microarray used in this study, SerpinA1 (Serpin peptidase inhibitor 
clade A member 1) transcript was shown to increase significantly following infection. This 
serpin is also known as α1-antitrypsin (AAT), a highly effective inhibitor of neutrophil 
elastase and one that plays an important role in coagulation, inflammation, and turnover of 
extracellular matrix. SerpinA1 also inhibits the activity of plasmin, thrombin, trypsin, 
chymotrypsin, and plasminogen activator. 
MCP1/CCL2 gene transcript in the family of cytokines and chemokines was significantly 
increased following Cpn infection. This transcript was the most dramatically altered 
following infection and has been recognized as a very important contributor to the 
inflammatory response observed in AD [65]. The MCP1/CCL2 protein has been shown to be 
increased in both CSF and plasma from individuals with mild cognitive impairment (MCI) 
and AD [66]. While the exact effects of MCP1/CCL2 in the MCI/AD brain are not fully 
understood, some experiments have shown that CCL2 may alter the properties of the BBB to 
allow for increased monocyte migration into brain tissues [67]. Furthermore, this chemokine 
may affect the production and clearance of Aβ amyloid from the brain [68]. Hence, although 
we did not measure the protein directly, the dramatic increase in this transcript would suggest 
that infection induction leading to such a large change is worthy of further evaluation. 
Conclusion 
Utilizing RT-PCR and ELISA techniques, our data demonstrate that Cpn infection of THP1 
human monocytes promotes an innate immune response, as pro-inflammatory gene 
transcripts and proteins showed significant fold increases. Furthermore, since research 
suggests that a chronic inflammatory state is present within the AD brain [10] and prior 
evidence has shown monocytes infected with Cpn in AD brains [1,3], we suggest that the 
pro- and chronic inflammatory states involved in AD pathogenesis may arise in part by Cpn 
infection of monocytes. These data are consistent with that of previous work suggesting that 
amyloid could be both a response to and an initiator of inflammation in the AD brain [22]. In 
effect, infection in the AD brain could initiate the inflammatory cascade that results in CNS 
damage reflected by amyloid production/processing and deposition. Inflammation generated 
by amyloid accumulation would then 'secondarily' result in extended damage via an 
inflammatory response generating ever increasing AD neuropathology. Further research to 
define the early events occurring in AD pathogenesis may help to clarify how infection with 
Cpn, and possibly other pathogens, may be an initiator of inflammation in sporadic LOAD. 
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